CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Centro de Atención Médica dedicado a la conducción de Estudios de Investigación Clínica en diferentes fases de desarrollo con más de 10 años de experiencia en diversas áreas de especialización.Arenales 1611 2 piso, C1061 Cdad. Autónoma de Buenos Aires, Argentina
Websitehttp://www.ciprec.org/es
Select an option
I am a doctor
I am a sponsor
Specializations
Diabetes
Gastroparesia diabética
Obesidad
Colangitis biliar primaria
Cardiovascular
Enfermedad renal crónica
Hígado graso
Covid-19
Our team
Medical staff
Lionel Wachs
Andrea Jokiel
Eliana Serrano
Fernando Guerlloy
Irene Copati
Agustina Bandoni
Agustina Filograsso
Lucia Helguera
Evelyn Garre
Diego Waserman
Ignacio Pintes
Mariela Bazan
Lucia Rey
Vanesa Espinosa
Paula Velasco
Julieta Bocci
Carolina Mastroberti
Amanda Gomez
Fernando Guerlloy - C
César Zaidman IP
Angela Romero Zarante
César Javier Zaidman
Fernando Gruz
Ezequiel Slutsky
Pablo Olivera Sendra
Noelia Broqua
Tania Zarowsky
Mariano Gabriel Marini
Open studies
Obesity
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) - ls (ATTAIN-HYPERTENSION - Eli Lilly and CompanySee more
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain - TRIUMPH-7 - Eli Lilly and CompanySee more
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 - ATTAIN-HYPERTENSION - Eli Lilly and CompanySee more
Arterial hypertension
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) - ls (ATTAIN-HYPERTENSION - Eli Lilly and CompanySee more
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 - ATTAIN-HYPERTENSION - Eli Lilly and CompanySee more
Breast Cancer
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease - FourLight-3 - PfizerSee more
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence - ELEGANT - Stemline Therapeutics, Inc.See more
Cardiovascular disease
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Heart failure
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more
Low Back Pain
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain - TRIUMPH-7 - Eli Lilly and CompanySee more
Hidradenitis suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) - RECHARGE 1 - Novartis PharmaceuticalsSee more
Hyperlipidemia
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) - MK-0616-037 - Merck Sharp & Dohme LLCSee more
Cholangitis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis - AFFIRM - Gilead SciencesSee more
Cirrhosis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis - AFFIRM - Gilead SciencesSee more
